Safety, Tolerability, and Changes in Amyloid β Concentrations After Administration of a γ-Secretase Inhibitor in Volunteers
Tóm tắt
Từ khóa
Tài liệu tham khảo
Jost, 1995, The natural history of Alzheimers disease: a brain bank study., J Am Geriatr Soc, 43, 1248, 10.1111/j.1532-5415.1995.tb07401.x
Schneider, 2001, Treatment of Alzheimers disease with cholinesterase inhibitors., Clin Geriatr Med, 17, 337, 10.1016/S0749-0690(05)70072-0
Reisberg, 2003, Memantine in moderate-to-severe Alzheimers disease., N Engl J Med, 348, 1333, 10.1056/NEJMoa013128
Tariot, 2004, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial., JAMA, 291, 317, 10.1001/jama.291.3.317
Selkoe, 1994, Normal and abnormal biology of the -amyloid precursor protein., Annu Rev Neurosci, 17, 489, 10.1146/annurev.ne.17.030194.002421
Schenk, 1995, Therapeutic approaches related to amyloid-beta peptide and Alzheimers disease., J Med Chem, 38, 4141, 10.1021/jm00021a001
Selkoe, 1998, The cell biology of beta-amyloid precursor protein and presenilin in Alzheimers disease., Trends Cell Biol, 8, 447, 10.1016/S0962-8924(98)01363-4
Bayer, 2001, Key factors in Alzheimers disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport., Brain Pathol, 11, 1, 10.1111/j.1750-3639.2001.tb00376.x
Selkoe, 1996, Cell biology of the beta-amyloid protein and the genetics of Alzheimers disease., Cold Spring Harb Symp Quant Biol, 61, 587, 10.1101/SQB.1996.061.01.059
Scheuner, 1996, Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimers disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimers disease., Nat Med, 2, 864, 10.1038/nm0896-864
Wolfe, 2001, The role of presenilins in gamma-secretase activity., J Biol Chem, 276, 5413, 10.1074/jbc.R000026200
Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimers disease in late onset families., Science, 261, 921, 10.1126/science.8346443
Corder, 1994, Protective effect of apolipoprotein E type 2 allele for late onset alzheimer disease., Nat Genet, 7, 180, 10.1038/ng0694-180
Reiman, 1996, Preclinical evidence of Alzheimers disease in persons homozygous for the 4 allele for apolipoprotein E., N Engl J Med, 334, 752, 10.1056/NEJM199603213341202
Saunders, 1993, Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimers disease., Neurology, 43, 1467, 10.1212/WNL.43.8.1467
Romas, 1999, APOE genotype, plasma lipids, lipoproteins, and AD in community elderly., Neurology, 53, 517, 10.1212/WNL.53.3.517
Holtzman, 2001, Role of apoe/Abeta interactions in the pathogenesis of Alzheimers disease and cerebral amyloid angiopathy., J Mol Neurosci, 17, 147, 10.1385/JMN:17:2:147
Games, 1995, Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein., Nature, 373, 523, 10.1038/373523a0
Gitter, 2004, Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma secretase inhibitor., Neurobiol Aging, 25, 571, 10.1016/S0197-4580(04)81897-9
Ness, 2004, Reduced -amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months., Neurobiol Aging, 25, 238, 10.1016/S0197-4580(04)80800-5
Siemers, 2004, Safety, tolerability, and changes in plasma and cerebrospinal fluid amyloid beta concentrations after administration of a functional gamma-secretase inhibitor in healthy volunteers., Neurobiol Aging, 25, 569, 10.1016/S0197-4580(04)81891-8
Siemers, 2004, Effect of LY450139, a functional -secretase inhibitor, on plasma and cerebrospinal fluid concentrations of A and cognitive functioning in patients with mild to moderate Alzheimers disease., Neurology, 62, A174
Wong, 2004, Chronic treatment with the -secretase inhibitor LY-411,575 inhibits -amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation., J Biol Chem, 279, 12876, 10.1074/jbc.M311652200
Searfoss, 2003, Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional -secretase inhibitor., J Biol Chem, 278, 46107, 10.1074/jbc.M307757200
De Strooper, 1999, A presenilin-1-dependent -secretase-like protease mediates release of Notch intracellular domain., Nature, 398, 518, 10.1038/19083
Zhang, 2000, Presenilins are required for gamma-secretase cleavage of -APP and transmembrane cleavage of Notch-1., Nat Cell Biol, 2, 463, 10.1038/35017108
Hartmann, 2001, Implication of APP secretases in notch signaling., J Mol Neurosci, 17, 171, 10.1385/JMN:17:2:171
Micchelli, 2003, Gamma-secretase/presenilin inhibitors for Alzheimers disease phenocopy Notch mutations in Drosophila., FASEB J, 17, 79, 10.1096/fj.02-0394fje
Yang, 2001, Requirement of math 1 for secretory cell lineage commitment in the mouse intestine., Science, 294, 2155, 10.1126/science.1065718
Hyslop, 2004, Reduction in A-beta(1-40) and A-beta(1-42) in CSF and plasma in the beagle dog following acute oral dosing of the gamma secretase inhibitor, LY450139., Neurobiol Aging, 25, 147, 10.1016/S0197-4580(04)80493-7
May, 2004, Multi-compartmental pharmaco-dynamic assessment of the functional gamma-secretase inhibitor LY450139 in PDAPP transgenic mice and non-transgenic mice., Neurobiol Aging, 25, 65, 10.1016/S0197-4580(04)80220-3
Shibata, 2000, Clearance of Alzheimers amyloid-1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier., J Clin Invest, 106, 1489, 10.1172/JCI10498
DeMattos, 2001, Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimers disease., Proc Natl Acad Sci U S A, 98, 8850, 10.1073/pnas.151261398
Kanai, 1998, Longitudinal study of cerebrospinal fluid levels of tau, A1-40, and A1-42(43) in Alzheimers disease: a study in Japan., Ann Neurol, 44, 17, 10.1002/ana.410440108
Andreasen, 1999, Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimers disease in patients with mild cognitive impairment., Neurosci Lett, 273, 5, 10.1016/S0304-3940(99)00617-5
Jensen, 1999, Cerebrospinal fluid Abeta42 is increased early in sporadic Alzheimers disease and declines with disease progression., Ann Neurol, 45, 504, 10.1002/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9
Graff-Radford, 2003, Longitudinal analysis of plasma A42 in subjects progressing from normal through mild cognitive impairment to Alzheimers disease., Neurology, 60, A245
Mehta, 2000, Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease., Arch Neurol, 57, 100, 10.1001/archneur.57.1.100
Mayeux, 2003, Plasma A40 and A42 and Alzheimers disease. Relation to age, mortality and risk., Neurology, 61, 1185, 10.1212/01.WNL.0000091890.32140.8F
Farlow, 2002, Basal A levels in plasma and cerebrospinal fluid of healthy subjects and patients with Alzheimer disease., Neurology, 58, A485
Hock, 2003, Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of Abeta 42 in patients with Alzheimers disease., Amyloid, 10, 1, 10.3109/13506120308995249